BioCryst Pharmaceuticals (BCRX) to Release Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is scheduled to issue its quarterly earnings data before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. The business’s revenue was up 34.9% compared to the same quarter last year. During the same period last year, the company earned ($0.28) EPS. On average, analysts expect BioCryst Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Down 1.3 %

Shares of BioCryst Pharmaceuticals stock opened at $7.02 on Friday. The stock’s fifty day moving average is $6.69 and its two-hundred day moving average is $5.77. The company has a market capitalization of $1.45 billion, a PE ratio of -6.56 and a beta of 1.88. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $7.93.

Insider Buying and Selling

In related news, Director Machelle Sanders sold 4,689 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the sale, the director now directly owns 27,742 shares in the company, valued at approximately $166,452. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Anthony Doyle acquired 36,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the purchase, the chief financial officer now directly owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Machelle Sanders sold 4,689 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $6.00, for a total value of $28,134.00. Following the sale, the director now owns 27,742 shares of the company’s stock, valued at $166,452. The disclosure for this sale can be found here. Insiders purchased 103,601 shares of company stock worth $596,338 in the last three months. 4.80% of the stock is owned by insiders.

Analyst Ratings Changes

BCRX has been the topic of several research analyst reports. JMP Securities upped their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.